Shield Therapeutics plc ("Shield" or the "Group") Completion of patient enrolment in pivotal AEGIS-CKD Phase 3 study
October 10, 2017 07:00 ET
|
Shield Therapeutics
LONDON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announces the completion of enrollment of the pivotal...
Shield Therapeutics plc ("Shield" or the "Group") US Composition of Matter Patent
September 06, 2017 07:00 ET
|
Shield Therapeutics
LONDON, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, is pleased to announce that the United States Patent and...
Shield Therapeutics plc to Present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017
August 31, 2017 09:00 ET
|
Shield Therapeutics
LONDON, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announced that Carl Sterritt, Chief Executive...
Interim Results for the six months ended 30 June 2016
September 20, 2016 08:42 ET
|
Shield Therapeutics
LONDON, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announces its preliminary Group results for...